

Index

A

- Adaptable lymphocyte hypothesis, 104–106
- Adjuvants
 - and immunomodulators, computational vaccinology
 - Alum, 13
 - G-protein couple receptors (GPCRs), 13
 - pharmacophore, 14
 - T cells (Tregs), 14
 - vaccination enhancement, 13
 - innate immunity, 139–140
- Allele Query Tool, 22, 23
- Allele search tools
 - Allele Query Tool, 37–38
 - flat file format, 38
 - Sequence Retrieval System (SRS) tool, 38–39
- AntiBP server, antibacterial peptides, 73–75
- AntigenDB database, 9
- Antigen-presenting cells (APCs), 146
- Artificial immune systems (AIS), tunable detectors
 - degeneration framework
 - algorithm framework, 118–119
 - patterns of response, 118
 - population pattern algorithm, parameter settings, 119–120
 - degeneration instantiation
 - algorithm, settings and response shape, 121–123
 - application and data, 121
 - k*-nearest neighbour, 123–125
 - pattern classification algorithm
 - PoRTuDe, 124–126
 - population patterns
 - algorithm, 114
 - antigens stimulation, 115
 - α parameter effects, 117
 - proliferation threshold effects, 116

- tunable activation threshold (TAT)
 - adaptable lymphocyte hypothesis, 104–106
 - behaviours, 106–107
 - dynamics, 105, 106

Artificial neural networks, 7

B

- Basic Formal Ontology (BFO), 51–52
- Bayesian multilevel analysis (BMLA), 158, 170–171
- Bioinformatic platform
 - asthma, 172–175, 183
 - Bayesian data analysis, 179
 - Bayesian multilevel data analysis, 170–171
 - network primer, 168
 - network properties, 169
 - primer, 166–168
 - domain exploration, 161–162
 - genetic association studies (GAS), 157
 - knowledge and data fusion
 - Bayesian logic module, 182
 - factual sources, 179
 - hybrid knowledge base, 180–181
- Markov-Blanket Membership (MBM)
 - probability, 172, 176–178
- Markov Blanket Sets (MBS), 172, 176
- multifactorial diseases
 - candidate gene studies, 159
 - database of genotypes and phenotypes (dbGaP), 161
 - genome wide association studies (GWAS), 159–160
- SNP association studies, DSS
 - GAS design, 171
 - issues, 165–166
 - methods, 163–165

- Bioinformatic platform (*cont.*)
 relevance of, 173–175
 selection process, 163, 165
 standard statistical methods, 172, 176
- Bioinformatics, databases, xiii
- Biological systems, immunology, xii
- Boolean models, xiii
- C**
- Calnexin, 145
- Candidate gene association studies, 159
- Cellular adaptive immunology
 CD1 presentation, 148–149
 major histocompatibility complex (MHC)
 molecule
 class II MHC expression, 146–148
 class I MHC molecules, 142–146
- ClinMalDB-US database, 8
- Common gateway interface (CGI), 36
- Computational vaccinology
 adjuvants and immunomodulators
 discovery
 Alum, 13
 G-protein couple receptors (GPCRs), 13
 pharmacophore, 14
 T cells (Tregs), 14
 vaccination enhancement, 13
- ageing, 15
- Alzheimer's disease, 16
- black death, 15
- disease pattern, 16
- epitope prediction
 B cells, 6–8
 T cells, 4–5
- infectious disease, 2, 15
- life-style vaccines, 3
- mortality rate, 1, 2
- Parkinson's disease, 16
- reverse vaccinology
 NERVE program, 10–11
 open reading frames (ORFs), 10
 subunit vaccines, 10
 surface proteins, 11
- subcellular location prediction, 9–10
- success features, 3
- vaccines delivery, vectors
 CpG optimisation, 13
 DyNAVacs, optimisation, 12
 plasmids, DNA vaccine, 12
- virulence factors (VF), identification, 8–9
- Conserved epitopes
 conserved fragments
 HIV-1 gp41, 99
 HIV-1 gp120 and solvent accessibility, 100
 RANKPEP T cell epitope predictions, 98
- materials and methods
 multiple protein-sequence alignments (MSAs), 96
 protein variability server (PVS), 96–97
 vaccine development, 95
 variability-masked sequence, 98, 99
- Copy number variations (CNVs),
 157, 161, 166
- Cytokines
 CTKPred, 72–73
 CytoPred, 73
- D**
- Data analysis, Bayesian immunogenomics
 Bayesian methods, 172
 MBM posteriors, 177
 multilevel data analysis, 170–171
 network primer, 168
 network properties, 169
 primer, 166–168
 standard statistical methods, 172
- Database of genotypes and phenotypes (dbGaP), 161
- Decision support system (DSS), SNP design,
 162–166
- Dendritic cells (DCs), 147
- Discotope, 7
- Distributed annotation system (DAS), HLA I.
See also TEPIDAS
 architecture, 58–59
 protocol, 58
 registry, 59
- Dizygotic (DZ) twins, 129
- DyNAVacs, vaccine optimisation, 12
- E**
- Elusive molecular self, defining, 153–154
- cellular adaptive immunity
 autophagic pathways, 147–148
 CD1 presentation, 148–149
 cell-surface antigen presentation, 142
 class II MHC expression, 146–148
 class I MHC molecules, 142–146
 cross presentation, 147
 dendritic cells (DCs), 147
 glycosylation, 141–142
 immunology dogma, 145
 intracellular peptide fragments, 142
 invariant chain (Ii), 146
 peptidases, 145–146

proteasome, 144
 ubiquitin, 144
 conjoined/Siamese twins, 130
 dizygotic (DZ) twins, 129
 epitope-paratope network, 133
 human symbiosis
 host-microbe interactions, 152
 microbiome, 151, 152
 tolerance, 151
 humoral adaptive immunity
 B cell epitopes, 149, 150
 sliding-window method, 150
 innate immunity
 adjuvants, 139–140
 drug-like adjuvants, 140
 NOD-like receptors (NLRs), 139
 PAMP and PRRs, 138–140
 monozygotic twins, 129–130
 network theory, 133
 non-self, 131–133
 Polly Matzinger's danger model, 131
 reductionist approaches
 autoimmunity, 137
 epigenetic inheritance, 135–136
 epigenetics, 135
 human genomes, 134
 post-translational modifications,
 136–137
 ubiquitination, 136
 self-positive model, 132
 Epitope prediction
 B cells
 artificial neural networks, 7
 complementary determining (CDR)
 loops, 6
 continuous and discontinuous epitopes,
 5–6
 paratope-epitope interaction, 6
 surface protein, 7
 MHC-peptide-TR binding
 comparison of, 87
 DQ3.2*b*, 85
 DR and DQ alleles, 85
 Dsg3 glycoprotein proteome,
 85, 86
 HIV-1 p24gag and gp160gag, 85
 T cells, 4–5
 European Searchable Tumour Cell-Line
 Database (ESTDAB), 30

F

File transfer protocol (FTP), 36, 42
 Fish Pathogen Database, 8

G

Gardasil, 3
 Genetic association studies (GAS), 157.
 See also Bioinformatic platform
 Genome wide association studies (GWAS),
 159–161
 Global Polio Eradication Program, 1

H

HensBC algorithm, 11
 Hidden markov models (HMMs), 5
 HLA database. *See* IMGT/HLA database
 Human immunodeficiency virus type 1
 (HIV-1) infection, 85
 Human leukocyte antigen class I (HLA I),
 60, 61, 64
 Human platelet antigens (HPA), 27–29
 Human symbiosis, elusive molecular self
 host-microbe interactions, 152
 microbiome, 151, 152
 tolerance, 151
 Humoral adaptive immunity
 B cell epitopes, 149, 150
 sliding-window method, 150

I

IMGT/HLA database
 accessing methods, 36–37
 allelic sequences, 33
 class I and II alleles, 34, 35
 clustal alignment tool, 39
 DRB1 consensus sequence, 40
 existing database, 34–36
 history of, 33–34
 tools
 alignment formats, 40–42
 allele search tools, 37–39
 developments, 42
 generalist databanks, 42–43
 new sequences submission, 42
 similar sequences searching,
 39–40
 Immune epitope database (IEDB), ontology
 development, 48–49
 objects, roles and processes, 52–53
 relationships, 53–55
 Immunomics, definition, xi, xii
 Immuno Polymorphism Database (IPD)
 centralised system, 21
 projects
 alignment interface, 27
 Allele Query Tool, 22, 23

- Immuno Polymorphism Database (IPD)
(*cont.*)
 european searchable tumour cell line
 database (ESTDAB), 30
 human platelet antigens (HPA),
 27–29
 killer-cell immunoglobulin-like
 receptors (KIR), 24–26
 major histocompatibility complex
 (MHC), 22–24
 sequence alignments, 26–27
- Immunovaccinology, xv
- Innate immunity
 adaptive immunity, 67
 adjuvants, 139–140
 drug-like adjuvants, 140
 innate immune database (IIDB),
 68–69
 innate immunity interactions database
 (innate DB), 69–70
 NOD-like receptors (NLRs), 139
 PAMPs, 68, 138–140
 PRRDB, 70–72
 PRRs, 138–140
 vaccines, 67
 web-based tools
 AntiBP, 73–75
 CTKPred, 72–73
 CytoPred, 73
- Invariant NKT (iNKT) cells, 149
- K**
- Killer-cell immunoglobulin-like receptors
 (KIR)
 Allele Entry, 25
 cell query tool, 25
 ligand calculator, 26
 Probe and Primer Search Tool, 26
- L**
- Leukocyte receptor complex (LRC).
See Killer-cell immunoglobulin-like
 receptors (KIR)
- Life-style vaccines, 3
- M**
- Major histocompatibility complex
 (MHC)
 class II MHC expression, 146–148
 class I MHC molecules, 142–146
- Immuno Polymorphism Database (IPD),
 22–24
 T cell epitope prediction, 5
- Major histocompatibility complex
 (MHC)-peptide-TR binding
 docking protocol
 binding register refinement, 84
 flanking residues extension, 84
 loop closure of, 83–84
 nonamer termini, 82–83
 procedure, flowchart of, 82
- epitope prediction
 comparison of, 87
 DQ3.2 β , 85
 DR and DQ alleles, 85
 Dsg3 glycoprotein proteome,
 85, 86
 HIV-1 p24gag and gp160gag, 85
- MHC-peptide Interaction Database - TR
 (MPID-T)
 gap index and gap volume, 80
 interface area and intermolecular
 hydrogen bonds, 79
- Ioga complex, analysis
 gap volume, 91
 H-bonds, 89
 LIGPLOT schematic
 diagram, 90
 space filling representation, 91
- supertype classification, 80–81
- TR/pMHC interaction
 C α trace ribbon representation, 89
 inter-residue interactions and
 schematic structure, 88
- Markov-Blanket Membership (MBM)
 probability, 172, 176–178
- MenB vaccine, 11
- MHC-peptide Interaction Database - TR
 (MPID-T)
 gap index and gap volume, 80
 interface area and intermolecular
 hydrogen bonds, 79
- Monozygotic (MZ) twins, 129–130
- Multifactorial diseases
 candidate gene association
 studies, 159
 database of genotypes and phenotypes
 (dbGaP), 161
 genome wide association studies
 (GWAS), 159
- Multiple protein-sequence
 alignments (MSAs),
 conserved epitopes, 96

O

- Ontology development, immune epitope database (IEDB)
 - Basic Formal Ontology (BFO) relationships, 51
- B cell receptors (BCRs), 48
- data consistency approaches, 49
- high level BFO/OBI structure, 52
- immunization assay, 50
- objects, roles and processes, 52–53
- Ontology for Biomedical Investigations (OBI), 51–52
- open biomedical ontologies (OBO), 51
- proxy for, 54, 55
- SARS coronavirus nucleoprotein, 50, 54, 55
- T cell epitope identification experiment, 54
- T cell receptors (TCRs), 48
- Ontology for Biomedical Investigations (OBI), 51–52
- ONTology of Immune Epitopes (ONTIE), 51–52
- Open biomedical ontologies (OBO), 51
- Open Reading Frames (ORF)-FINDER, 10

P

- PAMPs. *See* Pathogen associated molecular patterns
- Pathogen associated molecular patterns (PAMPs), 68, 138, 140
- Pattern recognition receptor database (PRRDB), 70–72
- Pattern-recognition receptors (PRRs), 68, 70, 138–140
- Population patterns, tunable detectors AIS algorithm, 114
 - antigens stimulation, 115
 - α parameter effects, 117
 - proliferation threshold effects, 116
- Protein variability server (PVS), conserved epitopes
 - Shannon Diversity Index (H) and metrics used, 97
 - T cell epitope predictions, 98
 - web interface, 96
- PRRs. *See* Pattern-recognition receptors (PRRs)

Q

- QSAR analysis techniques, 5

R

- Reverse vaccinology
 - NERVE program, 10–11
 - open reading frames (ORFs), 10
 - subunit vaccines, 10
 - surface proteins, 11

S

- Sequence Retrieval System (SRS) tool, 38–39
- Shannon Diversity Index (H), 97
- SignalP, 9–10
- Single nucleotide polymorphisms (SNPs). *See also* Bioinformatic platform
 - decision support system (DSS) issues, 165–166
 - methods, 163–165
 - selection process, 165
- GAS design, 171
- ratios and posteriors, 183
- SPICE graphical client, TEPIDAS
 - HLA-B*60 features, 64
 - viewer window, 63
 - zooming capability, 64
- Structural immunoinformatics. *See* Major histocompatibility complex (MHC)-peptide-TR binding
- Support vector machines (SVMs), 5

T

- T cell receptor (TR)/pMHC interaction. *See also* Major histocompatibility complex (MHC)-peptide-TR binding
 - $C\alpha$ trace ribbon representation, 89
 - inter-residue interactions and schematic structure, 88
- TEPIDAS
 - annotations, 60
 - distributed annotation system (DAS) architecture, 58–59
 - protocol, 58
 - registry, 59
 - query capabilities
 - features query, 61–62
 - XML response, 61
 - SPICE graphical client
 - HLA-B*60 features, 64
 - viewer window, 63
 - zooming capability, 64
- Toll-like receptors (TLRs), 138, 139

Tunable activation threshold (TAT), tunable detectors AIS
adaptable lymphocyte hypothesis, 104–106
antigen and T cell detector shapes, 111–113
dynamics, 105, 106
equation
 excitation, 109–110
 excitation index and activation threshold relationship, 107
 α parameter, 108–109
 perturbation, 109

U

UniProt code, 64

V

Vaccines, 67
VaxiJen, reverse vaccinology, 10
Virulence Factors Database (VFDB), 8–9

W

Web-based tools, innate immunity
 AntiBP
 query result page, 75
 submission form, 74
 CTKPred, 72–73
 CytoPred
 query result page, 74
 submission form, 73
WHO Nomenclature Committee for Factors,
 HLA System, 33–36, 38, 43